CStone Pharmaceuticals
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CSPHF research report →
About the company
CStone Pharmaceuticals is a biopharmaceutical firm dedicated to discovering, developing, and marketing innovative immuno-oncology and precision medicine therapies. Their primary objective is to fulfill critical medical requirements for cancer patients, both within China and across global markets. The company currently provides several key therapeutic agents.
- CEO
- Jianxin Yang
- IPO
- 2020
- Employees
- 135
- HQ
- Shanghai, CN
Price Chart
- Market Cap
- $951.23M
- P/E
- -22.71
- P/S
- 30.60
- P/B
- 11.11
- EV/EBITDA
- -26.65
- Div Yield
- 0.00%
- Gross Margin
- 39.88%
- Op Margin
- -120.09%
- Net Margin
- -123.30%
- ROE
- -64.78%
- ROIC
- -28.27%
- Revenue
- $262.63M · -35.51%
- Net Income
- $-425,725,766 · -366.77%
- EPS
- $-0.31 · -333.57%
- Op Income
- $-421,456,847
- FCF YoY
- 4.50%
- 52W High
- $1.01
- 52W Low
- $0.52
- 50D MA
- $0.84
- 200D MA
- $0.87
- Beta
- 0.25
- Avg Volume
- 3.46K
Get TickerSpark's AI analysis on CSPHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CSPHF coverage
Recent articles, reports, and earnings notes.
No research on CSPHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CSPHF report →Similar companies
Peers in the same neighborhood.